Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
IMRX 
Immuneering Corp (IMRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: IMRX (5-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $16.67
1 Year Target Price $16.67
| 2 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 270.8% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 403.46M USD | Price to earnings Ratio - | 1Y Target Price 16.67 |
Price to earnings Ratio - | 1Y Target Price 16.67 | ||
Volume (30-day avg) 5 | Beta 0.46 | 52 Weeks Range 1.10 - 10.08 | Updated Date 11/5/2025 |
52 Weeks Range 1.10 - 10.08 | Updated Date 11/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.9 |
Earnings Date
Report Date 2025-11-06 | When - | Estimate -0.4 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -68.37% | Return on Equity (TTM) -130.47% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 390593766 | Price to Sales(TTM) 563.62 |
Enterprise Value 390593766 | Price to Sales(TTM) 563.62 | ||
Enterprise Value to Revenue 191913.54 | Enterprise Value to EBITDA -1.53 | Shares Outstanding 63238699 | Shares Floating 26784809 |
Shares Outstanding 63238699 | Shares Floating 26784809 | ||
Percent Insiders 15.26 | Percent Institutions 35.55 |
Upturn AI SWOT
Immuneering Corp
Company Overview
History and Background
Immuneering Corp. is a biopharmaceutical company focused on developing translational bioinformatics to advance precision medicine, founded to address challenges in drug development and personalized healthcare. The company leverages its Disease Cancelling Technology platform to discover novel drug targets and biomarkers. The company IPO was on January 27, 2022.
Core Business Areas
- Drug Development: Immuneering develops and commercializes cancer therapeutics using its Disease Cancelling Technology platform.
- Translational Bioinformatics: The company provides bioinformatics services and tools to other pharmaceutical companies and researchers.
Leadership and Structure
Rahul Ramanathan is the President, CEO and Director. Benjamin Zeskind is the Co-Founder and CSO. The company has a Board of Directors overseeing strategic direction.
Top Products and Market Share
Key Offerings
- IMM-1-104: IMM-1-104 is Immuneering's lead product candidate, a novel RAF/MEK clamp, that is being developed to treat advanced RAS-mutant solid tumors. Market share is currently 0%, as the drug is in clinical development. Competitors include companies developing similar therapies, such as Mirati Therapeutics (MRTX), Revolution Medicines (RVMD), and Verastem Oncology (VSTM). Revenue from product is $0 as it is not commercially available yet.
- Disease Cancelling Technology platform: A proprietary platform used to identify novel drug targets and biomarkers by analyzing disease pathways. Platform license revenue is minimal.
Market Dynamics
Industry Overview
The biopharmaceutical industry is experiencing rapid growth driven by advances in genomics, personalized medicine, and targeted therapies. There is a focus on developing more effective and safer cancer treatments. The market is competitive and characterized by high R&D costs and long development timelines.
Positioning
Immuneering is positioned as a translational bioinformatics company, leveraging its proprietary platform to discover novel drug targets and biomarkers, with a focus on precision medicine. Its competitive advantage lies in its unique approach to disease pathway analysis and drug discovery.
Total Addressable Market (TAM)
The TAM for cancer therapeutics is estimated to be hundreds of billions of dollars globally. Immuneering is positioned to capture a portion of this market through the successful development and commercialization of its drug candidates. It has a small percentage of that TAM currently.
Upturn SWOT Analysis
Strengths
- Proprietary Disease Cancelling Technology platform
- Strong scientific team with expertise in bioinformatics and drug development
- Lead product candidate (IMM-1-104) with promising preclinical and clinical data
Weaknesses
- Early-stage company with limited revenue and a history of losses
- High dependence on the success of IMM-1-104
- Limited resources compared to larger pharmaceutical companies
Opportunities
- Potential to partner with larger pharmaceutical companies
- Expansion of the Disease Cancelling Technology platform to other therapeutic areas
- Growing demand for personalized medicine and targeted therapies
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles and lengthy approval processes
Competitors and Market Share
Key Competitors
- MRTX
- RVMD
- VSTM
Competitive Landscape
Immuneering faces competition from established pharmaceutical companies with more resources and experience in drug development. Its competitive advantage lies in its unique Disease Cancelling Technology platform and focus on precision medicine. Its current market share is essentially zero.
Growth Trajectory and Initiatives
Historical Growth: Immuneering's growth is primarily driven by advancing its lead product candidate, IMM-1-104, through clinical trials. The company has also focused on expanding its Disease Cancelling Technology platform.
Future Projections: Future growth depends on the successful clinical development and commercialization of IMM-1-104 and other pipeline candidates. Analyst estimates vary widely due to the inherent uncertainty in drug development.
Recent Initiatives: Initiatives include advancing IMM-1-104 through clinical trials, expanding the Disease Cancelling Technology platform, and exploring potential partnerships with larger pharmaceutical companies.
Summary
Immuneering Corp is a biotechnology company focusing on cancer therapeutics through its Disease Cancelling Technology platform, and the company's future hinges heavily on the success of IMM-1-104. The company currently has losses and has limited revenue. The company needs to successfully complete clinical trials to bring revenue or to partner with larger pharmaceutical companies. Competition is strong from companies with more resources.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Press releases
- Company Website
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual due diligence and consultation with a qualified financial advisor. Market data is delayed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Immuneering Corp
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2021-07-30 | Co-Founder, President, CEO & Director Dr. Benjamin J. Zeskind M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 54 | Website https://immuneering.com |
Full time employees 54 | Website https://immuneering.com | ||
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.